Abstract: Chronic exposure to drinking water contaminated with inorganic arsenic (iAs) is associated with an increased risk of urinary bladder (UB) cancers in humans. The exact role of specific iAs metabolite(s) in As-mediated carcinogenesis remains largely unknown. Experimental evidence suggests that trivalent arsenicals, namely arsenite (iAs III ) and two of its metabolites, monomethylarsonous acid (MMA III ) and dimethylarsinous acid (DMA III ), are possible proximate UB carcinogens. Here, we used a transcriptomics approach to examine perturbed molecular pathways in a human urothelial cell line (UROtsa) after short-term exposure to iAs III , MMA III and DMA III . Molecular pathways containing genes that encode proteins implicated in UB cancer development were perturbed by both MMA III and DMA III . These pathways included those of the extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase (ERK 1/2 MAPK) and nuclear factor kappa beta (NF-B). Together, these results may inform the current understanding of effects in the UB induced by acute As exposure and the relationship of these effects with As-mediated carcinogenesis.
INTRODUCTION
Chronic arsenic (As) exposure is associated with the development of cardiovascular disease, diabetes and various cancers [1] . The most common source of chronic As exposure worldwide is drinking water contaminated with inorganic forms of As (iAs) from natural, geologic sources [2, 3] . Inorganic As exists in drinking water as a mixture of two oxidation states, namely trivalent arsenite (iAs III ) and pentavalent arsenate (iAs V ), which predominate in anaerobic and aerobic conditions, respectively [4] . Millions of people worldwide and an estimated tens of millions in Bangladesh alone are exposed to iAs levels in drinking water that far exceed the World Health Organization's recommended limit of 10 ppb [5] [6] [7] .
Although iAs is classified as a known human carcinogen with primary targets of the skin, lung, and urinary bladder (UB) [8] , the mode of action (MOA) of iAs carcinogenesis remains largely undefined [9] [10] [11] . Experimental evidence supports the generation of oxidative stress as a major factor, which can contribute to carcinogenesis by causing macromolecule (e.g. DNA) damage and stimulating signaling pathways that control processes such as proliferation, differentiation and apoptosis [11] [12] [13] [14] . Arsenic can exert other potentially carcinogenic effects on cells that are not necessarily associated with oxidative stress. For instance, while they are not point mutagens, arsenicals can induce other genetic alterations such as chromosomal aberrations [15, 16] , can bind and inhibit enzymes [17] , and can influence gene expression by altering the epigenome [18] .
Determining which of these effects is a key event in As carcinogenesis is complicated by iAs III/V metabolism.
Arsenite and arsenate are biotransformed in humans and rodents to yield several trivalent and pentavalent methylated arsenical metabolites. During this process, individual methyl groups are added to iAs in a stepwise, unidirectional manner [19] . Chronic exposure to iAs III/V results in six major arsenicals in human urine in which 10-30% of the total As content exists as trivalent and pentavalent iAs (iAs III+V ), and 10-30% exists as the monomethylated forms monomethylarsonous acid (MMA III ) and monomethylarsonic acid (MMA V ). The remaining 60-80% exists as the trivalent/ pentavalent dimethylated species dimethylarsinous acid (DMA III ) and dimethylarsinic acid (DMA V ) [20] [21] [22] . One or more of these methylated arsenicals may contribute to the carcinogenic effect of chronic iAs exposure [23] . Not all methylated arsenicals have equivalent biological effects. For example, in general the trivalent arsenicals MMA III and DMA III are more cytotoxic in vitro than their pentavalent counterparts and iAs III/V [24] and have been considered likely carcinogenic arsenicals in vivo [25] .
Recently, we examined the gene expression profiles of normal human epidermal keratinocytes (NHEKs) after short-term exposure (24 h 
MATERIALS AND METHODS

Arsenicals
The arsenicals used in this study have been previously described [26] . Briefly, working solutions of sodium m-arsenite (NaAsO 2 ; herein referred to as iAs III ), monomethylarsonous acid in the form of (CH 3 )AsI 2 (MMA III ), and dimethylarsinous acid in the form of (CH 3 ) 2 AsI (DMA III ) were prepared in sterile phosphate buffered saline, pH 7.4 (PBS) immediately before use.
UROtsa Growth Conditions
UROtsas, a human urothelial cell line transformed by the large T antigen of SV40 [27] , were obtained from Dr. Zuzana Drobna (Department of Nutrition, UNC Gillings School of Global Public Health, University of North Carolina at Chapel Hill). UROtsas do not exhibit anchorage-independent cell growth and do not develop tumors in immunocompromised mice if maintained at low passage numbers [27, 28] . Routine UROtsa growth and subculturing conditions were as described by Rossi et al. [29] . UROtsas were grown in UROtsa growth medium which contained 1:1 DMEM/Ham's F12 media (GIBCO/Invitrogen, Carlsbad, CA) supplemented with 5% fetal bovine serum (FBS; Sigma-Aldrich, St. Louis, MO) [29] . Prior to arsenical treatment, the growth medium was removed, cells were washed briefly with PBS and the growth medium was replaced with 1:1 DMEM/Ham's F12 without FBS (UROtsa dosing medium). Cells were grown in a 37 o C, 5% CO 2 humid atmosphere in the absence of antibiotic and antifungal agents and matching cell line passages were used for all endpoint analyses.
Arsenical Treatment for Cytotoxicity Determination and Microarray Analysis
The UROtsas utilized in this study have been previously shown to be a suitable cell line to study the effects of individual arsenicals as they readily absorb them but have little [30] or no [24, 31, 32] 
RNA Extraction and RNA Processing
RNA was prepared from each lysed cell sample according to the TRIzol RNA extraction protocol (Invitrogen) followed by the RNeasy Mini Kit (Qiagen, Valencia, CA). RNA concentrations were determined spectrophotometrically (A 260 ). RNA quality was determined spectrophotometrically (A 260 /A 280 ) and by using the RNA 6000 Nano Assay with the 2100 Bioanalyzer (Agilent, Palo Alto, CA). For microarray analysis, 15 g of total RNA from each sample was converted to biotinylated cRNA using the Affymetrix 3' IVT Express Kit (cat #901228) as described by the manufacturer (Affymetrix, Santa Clara, CA). Total cRNA was then quantified using a NanoDrop ND-1000 Spectrophotometer (NanoDrop Technologies, Wilmington, DE) and evaluated for quality after fragmentation using a 2100 Bioanalyzer. The cRNA was hybridized to Affymetrix GeneChip® Human U133 Plus 2.0 arrays overnight at 45 o C in an Affymetrix GeneChip Hybridization Oven 640. Each chip was hybridized with cRNA obtained from one biological replicate. The hybridized arrays were washed and stained using a Fluidics Station 450 and scanned using a GeneChip Scanner 3000 7G according to the manufacturer's instructions (Affymetrix). After scanning, raw data (.cel files) were obtained using Affymetrix GeneChip® Command Console software (v. 3.0).
Microarray Analyses
Three biological replicates were used for each of the arsenical treatment groups and vehicle-treated controls. Robust Multiarray Average (RMA) was used for normalization and probe-level summarization [33] using Partek Genomics Suite ™ (version 6.5) software (Partek, Inc. St. Louis, MO). Differentially expressed genes (DEGs) after arsenical treatment compared to controls were identified using the following filters in Partek: 1-way ANOVA (p<0.05) followed by BenjaminiHochberg FDR (q<0.05) correction and >1.5 or <-1.5-fold change in expression. Hierarchical clustering was performed on genes that were differentially expressed in at least one arsenical treatment group relative to controls.
IPA software (version 8.8, Ingenuity® Systems, www.ingenuity.com) was used to analyze for enriched biological functions and molecular interactions associated with DEGs. The Ingenuity Knowledge Base within IPA is a literature-based database of known molecular interactions and functional annotations based on known relationships between cells, cellular components, drugs and diseases. For network generation, DEGs from each group were mapped to their corresponding object within the Ingenuity Knowledge Base. These objects were then overlaid on the global network of known molecular interactions, and smaller networks of interacting molecules within the global network were algorithmically generated based on their connectivity. Statistically significant associations of DEGs with biological functions and diseases (p<0.005) and canonical pathways (p<0.05) were also determined using IPA. All p values were calculated in IPA using a right-tailed Fisher's exact test, which calculates the probability that associated functions, pathways and network interactions were generated due to chance alone.
Quantitative Reverse Transcription-PCR (qRT-PCR)
The same total RNA preparations were used for microarray and qRT-PCR analyses. Quantitative RT-PCR was performed using the LightCycler® 480 RealTime PCR System (Roche Applied Science, Indianapolis, IN) using Qiagen's QuantiTect SYBR Green RT-PCR kit (cat. #204243) and QuantiTect® Primer Assays according to the One Step RT PCR Protocol. Each 50 l reaction contained 10 ng total RNA from a single biological sample, and three biological replicates were used for each treatment group and vehicle-treated controls. Beta actin (ACTB) was chosen for a reference target for each treatment group due to its stable expression in microarrays across all treatment groups. Expression levels of each target gene were normalized against ACTB expression within each treatment group and fold change values of the normalized target gene expression in arsenical treatment groups vs. vehicle-treated controls were calculated using the 2 -CT method [34] . Statistically significant changes in target expression levels between in arsenical treatment groups compared to vehicletreated controls was determined using a Student's ttest. The genes and QuantiTect primer assays that detect them were: ACTB as a reference target (Hs_ACTB_2_SG); dehydrogenase/reductase (SDR family) member 2 (DHRS2; Hs_DHRS2_1_SG) for the iAs III group; matrix metalloproteinase 1 (MMP1; Hs_MMP1_1_SG) and sodium channel, nonvoltagegated 1 alpha (SCNN1A; Hs_SCNN1A_1_SG) for MMA III group and MMP1 (Hs_MMP1_1_SG) and prostate transmembrane protein, androgen induced 1 (PMEPA1; Hs_PMEPA1_1_SG) for the DMA III group.
RESULTS
Transcriptional Response after Trivalent Arsenical Exposure
Arsenical concentrations that do not induce considerable cytoxicity/apoptosis have been shown to be relevant for studying perturbations in carcinogenic signaling pathways [14, 26, 35] targets selected for qRT-PCR showed the same direction of modulation compared to controls as observed in microarray experiments. All but PMEPA1 in the DMA III dose group had a statistically significant change in expression (p<0.01) in the treatment group vs. controls as determined by qRT-PCR (Figure 2) .
Overview of Statistically Significant Biological Functions and Canonical Pathways Associated with DEGs
DEGs from each of the arsenical treatment groups were analyzed for associated biological functions, diseases, and canonical pathways. Genes that play a role in immune response were particularly enriched in the DMA III group. These pathways contained many of the same upregulated pro-inflammatory genes such as interleukin 1, alpha (IL1A), interleukin 6 (IL6), interleukin 8 (IL8) and TNF ( Table 2B , Supplemental Material).
Molecular Networks Associated with DEGs
To identify genes that encode proteins that interact in the cell and therefore may represent a coordinated response to arsenical exposure, DEGs from each group were analyzed for molecular networks. The 763 DEGs in the MMA III group encode proteins that interact in 25 sub-networks ( Table 3 , Supplemental Material). ) of 137 total proteins including 59 encoded by DMA III -altered DEGs ( Figure 3B ).
We performed a detailed analysis of the most significant molecular networks (p<10 -24 ) generated in the MMA III and DMA III treatment groups. Networks in both groups contained signaling proteins that play a role in pathways implicated in cancer development that have been previously shown to be modulated by arsenical exposure, namely those involving ERK 1/2 MAPK and the transcription factor NF-B (Figure 3C-D  and 3E-F, respectively ). There were no common modulated genes among any of these ERK1/2 MAPK and NFnetworks. (Figure 3) .
Identification of UB Cancer-Associated DEGs
We examined the DEGs in the MMA III We previously determined that short-term exposure of NHEKs to trivalent arsenicals in vitro caused arsenical-specific effects in terms of the transcriptional modulation of genes implicated in the development of non-melanoma skin cancers (NMSCs) [26] . Here, we expanded this research effort to determine if genes associated with UB cancer development were modulated in UROtsas after short-term trivalent arsenical exposure. We report two key findings: (1) while the magnitude of the transcriptional responses were different between the arsenical groups, short-term exposure to both MMA III groups had a concordant direction of modulation compared to controls. Moreover, both groups were enriched for molecular networks containing signaling pathways associated with cancer development, namely the ERK1/2 MAPK and NF-B pathways. Carcinogenic effects associated with ERK 1/2 MAPK activation include stimulating proliferation, promoting cell migration and invasion, increasing genomic instability, and preventing apoptosis [66, 67] . NF-B can promote cancer development by stimulating proliferation, angiogenesis, and inflammation [13, 68] . NF-B and ERK 1/2 can be activated by reactive oxygen species (ROS) and are believed to play important roles in oxidative stress-related cancers associated with metal/metalloid (e.g. As) exposure [13] . Activation of these pathways has long been associated with As exposure in a variety of cell types and is believed to play major roles in As-mediated carcinogenesis through the modulation of genes involved in proliferation, development and inflammation [14, 35, 69] . Importantly, these biological functions (cellular proliferation/development and inflammation) are among the most significant functions associated with the ERK MAPK 1/2 and/or NF-B-containing molecular networks in the MMA III [24] and has recently been shown to be a multi-organ transplacental carcinogen [61] . Also, As-exposed populations with increased urinary MMA III+V /DMA III+V ratios have been associated with increased susceptibility to Asassociated cancers, including NMSCs and UB cancers [83] [84] [85] . It has been clearly established that DMA III can induce carcinogenic effects such as the production of ROS and DNA strand breaks and is the likely reactive metabolite contributing to UB cancers in DMA Vexposed rats [86] [87] [88] . [21, 89] . Therefore, taken together, these results suggest cell-specific responses to arsenicals and interindividual differences in iAs metabolism likely play important roles in the susceptibility to Asassociated disease. 
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